{"id":222740,"date":"2026-06-29T00:00:00","date_gmt":"2026-06-29T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041152-medtech-contrast-agents-and-radiopharmaceuticals-market\/"},"modified":"2026-07-21T11:07:19","modified_gmt":"2026-07-21T11:07:19","slug":"48000643-medtech-contrast-agents-and-radiopharmaceuticals-market-insights-united-states","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/48000643-medtech-contrast-agents-and-radiopharmaceuticals-market-insights-united-states\/","title":{"rendered":"Contrast Agents and Radiopharmaceuticals &#8211; Market Insights &#8211; United States"},"content":{"rendered":"<p>The US contrast agent and radiopharmaceutical market will witness\u00a0<span>moderate growth<\/span> over the forecast period. Growth will be driven by increasing <abbr title=\"Positron Emission Tomography\">PET<\/abbr> and <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr> procedure volumes, as well as broader adoption of imaging agents in <abbr title=\"Contrast-Enhanced Ultrasound\">CEUS<\/abbr> and <abbr title=\"Positron Emission Tomography\">PET<\/abbr> applications. However, market expansion will be constrained by ongoing concerns regarding gadolinium retention and radiation exposure associated with certain imaging modalities. In addition, the transition to value-based care will limit utilization of some procedures, favoring those that deliver superior diagnostic accuracy and visualization quality. Looking ahead, growth will be supported by the introduction of new contrast agents currently in development or clinical evaluation, as well as <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals that expand the indications of existing agents.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2035.<\/p>\n<p><strong>There has been a gradual increase in the number of\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals for <abbr title=\"Prostate-Specific Membrane Antigen\">PSMA<\/abbr> <abbr title=\"Positron Emission Tomography\">PET<\/abbr> imaging agents.<\/strong><\/p>\n<p>Which <abbr title=\"Prostate-Specific Membrane Antigen\">PSMA<\/abbr> <abbr title=\"Positron Emission Tomography\">PET<\/abbr> imaging agents have received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval?<\/p>\n<p>What advantages do these agents provide?<\/p>\n<p>What indications have been approved?<\/p>\n<p class=\"question-statement\"><strong>The <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0has expanded approval for the use of <abbr title=\"Contrast-Enhanced Ultrasound\">CEUS<\/abbr> in radiology procedures.<\/strong><\/p>\n<p>What types of procedures does this approval extend to, and what additional procedures could potentially be approved in the future?<\/p>\n<p>Which contrast agents have received <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval?<\/p>\n<p>How will these <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals affect the competitive landscape?<\/p>\n<p><strong>Investments in <abbr title=\"Positron Emission Tomography\">PET<\/abbr> production, cyclotron networks, and theranostics infrastructure are becoming increasingly important competitive differentiators.<\/strong><\/p>\n<p>Which companies are expanding their <abbr title=\"Positron Emission Tomography\">PET<\/abbr> and theranostics capabilities?<\/p>\n<p>How will these investments improve radiopharmaceutical availability and distribution?<\/p>\n<p class=\"question-statement\"><b>Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr>.<\/b><\/p>\n<p>How are <abbr title=\"Accountable Care Organization\">ACO<\/abbr>s, health networks, and physicians responding to the recent findings on gadolinium retention?<\/p>\n<p>What are the key differences between linear and macrocyclic <abbr title=\"Gadolinium-Based Contrast Agent\">GBCA<\/abbr>s, and how will market demand for these products shift going forward?<\/p>\n<p>Will other imaging modalities cannibalize contrast-enhanced <abbr title=\"Magnetic Resonance Imaging\">MRI<\/abbr> procedures?<\/p>\n<p>Which companies (and associated products) will benefit from the shift to macrocyclic <abbr title=\"Gadolinium-Based Contrast Agent\">GBCA<\/abbr>s?<\/p>\n<p><strong>Supply-chain resilience is becoming an important competitive consideration in the radiopharmaceutical and contrast agent market.<\/strong><\/p>\n<p>How are companies addressing radioisotope availability, contrast media supply risks, and radiopharmacy distribution needs?<\/p>\n<p>How could tariffs, domestic production initiatives, and nuclear pharmacy networks affect future competitive positioning?<\/p>\n","protected":false},"template":"","class_list":["post-222740","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-contrast-agents-and-radiopharmaceuticals","medtech-therapy-area-imaging","medtech-geography-united-states","medtech-date-2828"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/222740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=222740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}